Skip to main content

Michael Eaddy, PharmD, PhD

Authored Items
Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis
Jeffrey T. Guptill, MD, MA, MHS, James T. Kenney, RPh, MBA, Michael C. Runken, PharmD, Michael Eaddy, PharmD, PhD, Orsolya Lunacsek, PhD, Rupali M. Fuldeore, MS
May 2019 Vol 12, No 3 in Original Research
Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization Algorithm
Jordan S. Orange, MD, PhD, Gary Branning, MBA, Matt Johnson, BA, Barbara Lennert, RN, BSN, MAOM, Katarzyna Shields, PharmD, MBA, BCOP, BCPS, Michael Eaddy, PharmD, PhD
May 2017 Vol 10, No 3 in Original Research
Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea
Todd Williamson, PhD, MSc, Atheer A. Kaddis, PharmD, Rajesh Kamalakar, MS, Augustina Ogbonnaya, MPH, Erin A. Zagadailov, PharmD, MS, Michael Eaddy, PharmD, PhD, Charlie Kreilick, MBA
May 2017 Vol 10, No 3 in Original Research
Treatment Patterns and Outcomes in Patients with Varicose Veins
Rajiv Mallick, PhD, Aditya Raju, MS, BPharm, Chelsey Campbell, PharmD, MBA, Rashad Carlton, PharmD, MSPH, David Wright, MD, Kimberly Boswell, MD, Michael Eaddy, PharmD, PhD, Gary M. Owens, MD
November 2016 Vol 9, No 8 in Original Research
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS, Gary Branning, MBA, Dinara Makenbaeva, MD, MBA, Michael Eaddy, PharmD, PhD
December 2015 Vol 8, No 9 in Original Research, Practice Management
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease
Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD
October 2015 Vol 8, No 7 in Original Research, Practice Management
Sensitivity of Medication Use to Formulary Controls in Medicare Beneficiaries: A Review of the Literature
Rahul Shenolikar, PhD, Gary M. Owens, MD, Amanda Schofield Bruno, PhD, MPH, Christopher Cantrell, PhD, Michael Eaddy, PharmD, PhD
November/December 2011, Vol4, No7 in Practice Management
The Economic Impact of Delaying 5-Alpha Reductase Inhibitor Therapy in Men Receiving Treatment for Symptomatic Benign Prostatic Hyperplasia
Michael Naslund, MD, MBA, Matthew Mitchell, PharmD, MBA, FAMCP, Michael Eaddy, PharmD, PhD, Susan L. Hogue, PharmD, MPH, Eric J. Kruep, PharmD, MS, Manan B. Shah, PharmD, PhD
May/June 2011, Vol 4, No 3 in Original Research, Practice Management
Last modified: April 23, 2019